Total Payments
$348,378
2024 Payments
$39,186
Companies
91
Transactions
1,463
Medicare Patients
12,045
Medicare Billing
$13.4M
Payment Breakdown by Category
Other$265,331 (76.2%)
Consulting$29,458 (8.5%)
Food & Beverage$27,006 (7.8%)
Travel$26,201 (7.5%)
Education$383.37 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $265,331 | 99 | 76.2% |
| Consulting Fee | $29,458 | 15 | 8.5% |
| Food and Beverage | $27,006 | 1,285 | 7.8% |
| Travel and Lodging | $26,201 | 49 | 7.5% |
| Education | $383.37 | 15 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $227,954 | 241 | $0 (2024) |
| Daiichi Sankyo Inc. | $75,763 | 81 | $0 (2024) |
| Genentech USA, Inc. | $14,620 | 110 | $0 (2024) |
| Seagen Inc. | $4,027 | 28 | $0 (2023) |
| Merck Sharp & Dohme LLC | $3,115 | 40 | $0 (2024) |
| Astellas Pharma US Inc | $2,239 | 42 | $0 (2024) |
| AstraZeneca UK Limited | $2,055 | 1 | $0 (2023) |
| Eisai Inc. | $1,981 | 29 | $0 (2024) |
| Lilly USA, LLC | $1,255 | 98 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,199 | 63 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,186 | 196 | AstraZeneca Pharmaceuticals LP ($26,294) |
| 2023 | $99,027 | 235 | AstraZeneca Pharmaceuticals LP ($50,461) |
| 2022 | $75,381 | 177 | AstraZeneca Pharmaceuticals LP ($45,819) |
| 2021 | $57,597 | 145 | AstraZeneca Pharmaceuticals LP ($54,935) |
| 2020 | $26,268 | 134 | AstraZeneca Pharmaceuticals LP ($20,995) |
| 2019 | $38,535 | 212 | AstraZeneca Pharmaceuticals LP ($29,123) |
| 2018 | $2,685 | 189 | Lilly USA, LLC ($349.32) |
| 2017 | $9,699 | 175 | Genentech USA, Inc. ($7,309) |
All Payment Transactions
1,463 individual payment records from CMS Open Payments — Page 1 of 59
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $4.09 | General |
| Category: Interventional Oncology | ||||||
| 12/31/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $3.72 | General |
| Category: Interventional Oncology | ||||||
| 12/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Rare Disease | ||||||
| 12/16/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.55 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Oncology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.50 | General |
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Oncology | ||||||
| 12/09/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.21 | General |
| 12/04/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $24.86 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $7.83 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: BioOncology | ||||||
| 11/18/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: Genetic Disease | ||||||
| 11/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,920.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.62 | General |
| 11/13/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $379.40 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $66.10 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Oncology | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 46 | 3,260 | 297,171 | $8.9M | $2.9M |
| 2022 | 42 | 2,809 | 305,099 | $6.7M | $2.8M |
| 2021 | 43 | 2,842 | 382,713 | $7.0M | $3.4M |
| 2020 | 48 | 3,134 | 418,270 | $9.1M | $4.3M |
Total Patients
12,045
Total Services
1,403,253
Medicare Billing
$13.4M
Procedure Codes
179
All Medicare Procedures & Services
179 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 24 | 29,800 | $2.7M | $1.3M | 48.1% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 49 | 3,881 | $1.4M | $340,459 | 23.7% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 63 | 95,900 | $959,000 | $228,425 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 583 | 1,750 | $384,850 | $174,191 | 45.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 77 | 9,480 | $379,200 | $167,744 | 44.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 113 | 1,167 | $375,880 | $125,625 | 33.4% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 12 | 3,300 | $231,000 | $111,655 | 48.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 178 | 458 | $119,775 | $66,399 | 55.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 170 | 4,678 | $257,290 | $59,989 | 23.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 31 | 3,200 | $144,000 | $49,183 | 34.2% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 42 | 51,750 | $129,375 | $45,314 | 35.0% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 92 | 461 | $32,270 | $32,242 | 99.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 54 | 392 | $62,720 | $21,291 | 33.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 277 | $51,245 | $16,779 | 32.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 91 | 91 | $28,095 | $16,243 | 57.8% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 12 | 1,942 | $242,750 | $14,280 | 5.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 176 | 1,206 | $60,250 | $13,661 | 22.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 56 | 441 | $33,000 | $10,638 | 32.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 85 | 188 | $31,960 | $9,852 | 30.8% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 47 | 48,016 | $240,080 | $7,888 | 3.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 184 | 1,518 | $7,590 | $7,418 | 97.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 48 | 194 | $24,250 | $5,306 | 21.9% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 145 | 1,146 | $28,650 | $4,974 | 17.4% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 19 | 157 | $16,485 | $4,889 | 29.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 43 | 3,941 | $197,050 | $4,090 | 2.1% |
About Sameer Gupta, MD, MPH
Sameer Gupta, MD, MPH is a Hematology & Oncology healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2008. The National Provider Identifier (NPI) number assigned to this provider is 1013171420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sameer Gupta, MD, MPH has received a total of $348,378 in payments from pharmaceutical and medical device companies, with $39,186 received in 2024. These payments were reported across 1,463 transactions from 91 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($265,331).
As a Medicare-enrolled provider, Gupta has provided services to 12,045 Medicare beneficiaries, totaling 1,403,253 services with total Medicare billing of $13.4M. Data is available for 4 years (2020–2023), covering 179 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Bryn Mawr, PA
- Active Since 07/15/2008
- Last Updated 04/05/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013171420
Products in Payments
- LYNPARZA (Drug) $52,797
- TAGRISSO (Drug) $50,067
- Enhertu (Drug) $48,264
- IMFINZI (Drug) $42,479
- ENHERTU (Biological) $38,747
- ENHERTU (Drug) $27,400
- CALQUENCE (Drug) $14,821
- IMFINZI (Biological) $12,320
- Perjeta (Biological) $4,494
- Herceptin (Biological) $4,182
- PADCEV (Biological) $3,786
- Avastin (Biological) $3,195
- KEYTRUDA (Biological) $3,019
- Kadcyla (Biological) $2,351
- Padcev (Drug) $1,556
- Halaven (Drug) $1,519
- XARELTO (Drug) $653.04
- VERZENIO (Drug) $559.79
- OPDIVO (Biological) $557.94
- IMBRUVICA (Drug) $548.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Bryn Mawr
Dr. John Devlin, M.d, M.D
Hematology & Oncology — Payments: $29,172
Hematology & Oncology $29,172
Eric Fox
Hematology & Oncology — Payments: $11,916
Hematology & Oncology $11,916
Dr. Sandra Schnall, M.d, M.D
Hematology & Oncology — Payments: $10,386
Hematology & Oncology $10,386
Dr. John Garofalo, Md, MD
Hematology & Oncology — Payments: $15.05
Hematology & Oncology $15.05